A Study to Evaluate Solriktug in Adult Participants With Asthma

Prior treatment

• Participant has an exacerbation of asthma requiring use of OCS or hospitalization in the 6 weeks prior to Screening or during the Screening Period.
• Lower respiratory tract infection within the 6 weeks prior to Screening.

Other illness

• Participant is a current smoker, or former smoker with a smoking history of ≥10 pack-years.
• Participant has a known hypersensitivity to any component of the formulation of solrikitug, including any of the excipients, or a history of anaphylactic reaction to any therapeutic monoclonal antibody.
• Participant has history or evidence of any clinically significant cardiovascular, hematologic, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy, or any other condition (risks factors of pneumonia) that in the opinion of the Investigator might obfuscate the study data.
• Participant has history or evidence of any clinically significant pulmonary condition, other than asthma.

Other

• Female participant who is pregnant or breastfeeding.

• Participant must be aged 18 to 75 years of age.
• Documented diagnosis of asthma at least 12 months prior to Screening.
• Participants must be on maintenance asthma medications, for at least 3 months prior to screening: inhaled corticosteroid (ICS) in combination with long-acting beta agonist (LABA), or as part of an approved triple therapy for asthma (ICS/LABA/long-acting muscarinic antagonist \[LAMA\]).
• Participant has an ACQ-6 score ≥1.5 at Screening Visit.
• Participant has FEV1 of ≥50% to 90%, inclusive, of predicted normal value at Screening Visit 1.
• Evidence of asthma as documented by reversibility in FEV1 of ≥12% and ≥200 mL over the pre-salbutamol FEV1 at Screening Visit.